Google article if interested, "William Blair Reiterates “Outperform” Rating for Nektar Therapeutics (NKTR)"
They will definitely be in the boat. This is fast tracked for a reason. FDA and medical community are beside themselves, with no good answers, for the OVER, 35,000 folks we lose a year to pain killer overdoes. They/we need a silver bullet. More eyes on 181 than most realize.
Wow, you really should not invest in things you don't understand. Opioids, as in REAL Opioids, have experience the same non rebound effect when subjects were switched to placebo. Think about it. LOL :-)
Players play, but THIS DRUG WORKS. Sorry.
Listen to the call, then you will understand, or just sell and get out. If you don't have the time to do the DD, your best to bet is a mutual fund.
Sure, just as a cancer drug is different form a hep c drug, but acquisitions in ANY of the biotech's, serves to REMIND people that smart money is on the hunt for bargains, and draws bidders. Happens every time. It draws attention to ALL players, particularly those that are undervalued, given current overhang in the market, i.e., hospital/insurance/washington uncertainty that exists. Shows Stryker sees plenty of opportunity, believes the clouds are clearing for hospital capitol spending, and is ready to step in for the long term.